Krystal Biotech, Inc.

NASDAQ:KRYS

158.33 (USD) • At close January 3, 2025
Bedrijfsnaam Krystal Biotech, Inc.
Symbool KRYS
Munteenheid USD
Prijs 158.33
Beurswaarde 4,553,649,965
Dividendpercentage 0%
52-weken bereik 107.5 - 219.34
Industrie Biotechnology
Sector Healthcare
CEO Mr. Krish S. Krishnan M.B.A., M.S.
Website https://www.krystalbio.com

An error occurred while fetching data.

Over Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved

Vergelijkbare Aandelen

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.81 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

18.86 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

46.26 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

40.51 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

124.59 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

110.56 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

12.94 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

11.67 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

36.92 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)